Industry news

Price check at FDA: Trump pushes for pharma ads with dollar signs

Beth Snyder Bulik / FiercePharma

When President Trump unveiled his drug-pricing agenda, pharma marketers and ad agencies were surprised by one proposal in particular: drug prices in TV ads. The administration has since doubled down on the idea, leaving marketers with a host of questions about how and why.

Note to pharma: AI companies could use your help detailing doctors

Carly Helfand / FiercePharma

Artificial Intelligence companies are coming up with all kinds of ways to help pharma improve clinical trials, zero in on which patients will benefit most from their drugs and go well beyond the pill. So how can pharma return the favor? By convincing reluctant doctors to jump on board, for starters.

Russian developers of new antibiotics will be subsidized by the government

GMP News

More than half of antibiotics sold in Russia are manufactured locally, said the Deputy Minister of industry and Trade of Russia Sergey Tsyb at the meeting of the Expert Council on Health Care under the Federation Council Committee on Social Policy. According to the official, today, Russian companies are actively investing and working on new generation antibiotics. The Deputy Minister of Industry and Trade said that the development of new antibiotics is a priority project for the Ministry.

The Russian Federation is preparing data integrity guidance for pharma industry

GMP News

The State Institute for Drugs and Good Practices (SID&GP), a federal budget-funded institution, and PQE Group are working together on elaborating an industry data integrity guidance. The guidance will be prepared in order to develop the requirements for good manufacturing practices (GMP) with regard to the manufacturing of pharmaceutical substances and medicinal products.

Russian drugs are increasing their share in oncology and hepatitis market segments

GMP News

In 2017, the share of Russian medicines for the treatment of oncological diseases reached almost 50% in this market segment. Over the past five years (since 2012), this figure increased by 3.6 times (from 13.2% to 46.9%). This is confirmed by the data released in the report of the Russian Ministry of Industry and Trade for 2017.

49% of cancer drugs purchased by Russian Ministry were manufactured in Russia

GMP News

According to IQVIA, in 2017, the Russian market of anti-tumor drugs was about 72 billion rubles in value terms and amounted to 14 million packages in physical terms. Compared to 2016, the sales of medicinal products in this segment increased by 10% in value terms and 19% in physical terms.

Top pharma players place their stakes on Chinese market

GMP News

International drug producers have had good performances in China in recent years. Pharmaceutical giant Bayer reported a robust growth in its pharmaceutical business in China, as its total sales stood at 17 billion yuan ($2.67 billion) in 2017, a year-on-year growth of 18.3 percent.

Drugmakers are down with AI, experts agree. They're just not sure what to use it for

Carly Helfand / FiercePharma

Pharma’s plenty enthusiastic when it comes to artificial intelligence. The thing is, companies aren’t exactly sure yet how they should be using it. That was the prevailing opinion at a recent roundtable in the AI hotbed of Montreal, Canada, where the Government of Quebec—which recently rolled out an ambitious plan to become a top-5 sector hub in North America by 2027—assembled pros from across the field to discuss the state of AI today.

Clinical trials in the New Health Economy: Digital tools and data driving awareness, engagement and retention

PWC

New digital tools and services can help biopharmaceutical companies overcome the delays and bottlenecks endemic to drug research and development and can improve patient experiences and retention during clinical trials. Making trial participation more convenient and relevant to patients can help bring new drugs to market more rapidly and distinguish products in competitive therapeutic areas.

09 May 2018

Clearside Biomedical Announces First Quarter 2018 Financial Results and Provides Corporate Update

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reported financial results for the quarter ended  March 31, 2018 , and provided an update on its development programs.